Listening to Dr. Patterson makes me feel how far behind we are in this LH and covid effect, having to retrace his path simply because we have a drug that is not yet approved. He has already gained a lot of bio-marker understanding of what is happening and has designed the protocol which he claims is already working well. We are now looking to discover such knowledge based on how LL works.
It seems that because they are using an approved drug Maravoric, they don't have to go through the FDA to treat patients [even though it is for a new indication "Long Covid"], can experiment and conduct de facto trials and get data etc. We have to go through hell to get any trial going with a comparably minuscule number of patients.
Eventually we have to show Leronlimab does the same job that Dr. Patterson has already established through Maravoric and make a case that LL can either work better or serve as an alternate CCR5 antagonist. Hopefully this will happen within the next year.
News 
Market Data 
Discover 
